Epicrispr Receives $8M CIRM Grant

Epicrispr Biotechnologies receives an $8 million grant from the California Institute for Regenerative Medicine to fund its first-in-human trial of EPI-321. This award ranks above roughly 94% of comparable grant rounds in the US healthcare sector. The funding follows a $90 million Series C closed in August and supports a therapy targeting facioscapulohumeral muscular dystrophy.